4//SEC Filing
ACURA PHARMACEUTICALS, INC 4
Accession 0001209191-15-003773
$ACURCIK 0000786947operating
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 6:21 PM ET
Size
18.7 KB
Accession
0001209191-15-003773
Insider Transaction Report
Form 4
CLAUDIUS LLC
10% Owner
Transactions
- Sale
Common Stock
2015-01-12$0.64/sh−35,000$22,456→ 10,957,621 total(indirect: See FN) - Sale
Common Stock
2015-01-08$0.60/sh−100,000$60,180→ 11,028,621 total(indirect: See FN) - Sale
Common Stock
2015-01-09$0.65/sh−36,000$23,436→ 10,992,621 total(indirect: See FN)
GALEN PARTNERS INTERNATIONAL III L P
10% Owner
Transactions
- Sale
Common Stock
2015-01-12$0.64/sh−35,000$22,456→ 10,957,621 total(indirect: See FN) - Sale
Common Stock
2015-01-09$0.65/sh−36,000$23,436→ 10,992,621 total(indirect: See FN) - Sale
Common Stock
2015-01-08$0.60/sh−100,000$60,180→ 11,028,621 total(indirect: See FN)
GALEN PARTNERS III L P
10% Owner
Transactions
- Sale
Common Stock
2015-01-12$0.64/sh−35,000$22,456→ 10,957,621 total(indirect: See FN) - Sale
Common Stock
2015-01-08$0.60/sh−100,000$60,180→ 11,028,621 total(indirect: See FN) - Sale
Common Stock
2015-01-09$0.65/sh−36,000$23,436→ 10,992,621 total(indirect: See FN)
GALEN EMPLOYEE FUND III LP
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$0.60/sh−100,000$60,180→ 11,028,621 total(indirect: See FN) - Sale
Common Stock
2015-01-09$0.65/sh−36,000$23,436→ 10,992,621 total(indirect: See FN) - Sale
Common Stock
2015-01-12$0.64/sh−35,000$22,456→ 10,957,621 total(indirect: See FN)
Galen Management, LLC
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$0.60/sh−100,000$60,180→ 11,028,621 total(indirect: See FN) - Sale
Common Stock
2015-01-09$0.65/sh−36,000$23,436→ 10,992,621 total(indirect: See FN) - Sale
Common Stock
2015-01-12$0.64/sh−35,000$22,456→ 10,957,621 total(indirect: See FN)
Footnotes (9)
- [F1]The shares were sold as follows: 91,356 by Galen Partners III, L.P. ("Galen III"), 8,268 by Galen Partners International III, L.P. ("Galen International") and 376 by Galen Employee Fund III, L.P. ("Employee Fund").
- [F2]The shares were sold at prices between $0.59 and $0.621. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The shares are held as follows: 10,078,319 by Galen III, 908,784 by Galen International and 41,518 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F4]The shares were sold as follows: 32,888 by Galen III, 2,977 by Galen International and 135 by Employee Fund.
- [F5]The shares were sold at prices between $0.64 and $0.66. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The shares are held as follows: 10,045,431 by Galen III, 605,807 by Galen International and 41,383 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F7]The shares were sold as follows: 31,974 by Galen III, 2,894 by Galen International and 132 by Employee Fund.
- [F8]The shares were sold at prices between $0.62 and $0.67. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F9]The shares are held as follows: 10,013,457 by Galen III, 902,913 by Galen International and 41,251 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
Documents
Issuer
ACURA PHARMACEUTICALS, INC
CIK 0000786947
Entity typeoperating
IncorporatedNY
Related Parties
1- filerCIK 0000786947
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 6:21 PM ET
- Size
- 18.7 KB